Boothbay Fund Management, LLC Abb Vie Inc. Transaction History

Boothbay Fund Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $2.14 Million - $2.72 Million	15,563 New	15,563 $2.38 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $3.07 Million - $3.88 Million	-28,545 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $3.04 Million - $3.45 Million	28,545 New	28,545 $3.08 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $394,642 - $439,654	-3,751 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $1.68 Million - $1.85 Million	-16,406 Reduced 81.39%	3,751 $406,000
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $1.55 Million - $2.09 Million	-19,204 Reduced 48.79%	20,157 $2.16 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $2.43 Million - $2.85 Million	28,287 Added 255.44%	39,361 $3.45 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $251,072 - $335,971	3,422 Added 44.72%	11,074 $1.09 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $493,554 - $748,289	7,652 New	7,652 $583,000
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $1.02 Million - $1.27 Million	-14,073 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $886,317 - $1.07 Million	14,073 New	14,073 $1.07 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $311,400 - $384,040	-4,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $160,038 - $177,912	-1,800 Reduced 31.03%	4,000 $378,000
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $1.47 Million - $1.74 Million	-16,403 Reduced 73.88%	5,800 $537,000
Q1 2018 May 14, 2018	BUY	$92.01 - $123.21 $2.04 Million - $2.74 Million	22,203 New	22,203 $2.1 Million

3,870

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.